Teva
Israel - Petach Tikva
OXYMORPHONE HYDROCHLORIDE by Teva is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2011.
Drug data last refreshed 20h ago
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxymorphone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxymorphone. Clinically, dosage is titrated to provide adequate analgesia…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
Worked on OXYMORPHONE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.